DRI Healthcare Trust Acquires Royalty Interest in KalVista's Seb способов лечения Hereditary Angioedema Drug
• DRI Healthcare Trust has acquired a royalty interest in sebetralstat, an oral on-demand therapy for hereditary angioedema (HAE), from KalVista Pharmaceuticals.
• The agreement includes an upfront payment of US$100 million, potential milestone payments up to US$57 million, and a US$5 million equity investment in KalVista.
• Seb способов лечения Hereditary Angioedema is under regulatory review by the FDA and EMA, with a PDUFA date set for June 17, 2025.
• The investment aligns with DRI Healthcare Trust's strategy to finance innovation in the life sciences and diversify its portfolio with long-term assets.
© Copyright 2025. All Rights Reserved by MedPath